Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity
Khaleel I. Al‐Obaidy(Indiana University School of Medicine), David J. Grignon(Indiana University School of Medicine), Muhammad T. Idrees(Indiana University School of Medicine), John N. Eble(Indiana University – Purdue University Indianapolis), Mehdi Nassiri(Indiana University School of Medicine), Mohammad K. Eldomery(St. Jude Children's Research Hospital), Liang Cheng(Brown University), Nilesh Gupta(Henry Ford Health System), Sean R. Williamson(Cleveland Clinic), Wael Sakr(Wayne State University), Oudai Hassan(Henry Ford Health System)
Cited by 75
Related Papers
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
|Modern Pathology|2017|404
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
|PubMed|2002|383
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
|Cancers|2021|289